TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia

Cold Spring Harbor Perspectives in Medicine
Evan Q Comeaux, C G Mullighan

Abstract

Acute lymphoblastic leukemia (ALL) is an aggressive neoplasm of B- or T-lymphoid progenitors and is the commonest childhood tumor. ALL comprises multiple subtypes characterized by distinct genetic alterations, with stereotyped patterns of aneuploidy present in many cases. Although alterations of TP53 are common in many tumors, they are infrequent in ALL, with the exception of two ALL subtypes associated with poor outcome: relapsed disease and ALL with hypodiploidy. TP53 alterations are present in almost all cases of ALL with low hypodiploidy and are associated with alterations of the lymphoid transcription factor IKZF2 and the tumor-suppressor gene loci CDKN2A and CDKN2B. Remarkably, more than half of TP53 mutations in low-hypodiploid ALL in children are present in nontumor cells, indicating that low-hypodiploid ALL is a manifestation of Li-Fraumeni syndrome. These findings have profound implications for our understanding of the genetic pathogenesis of hypodiploid ALL, suggesting that alteration of TP53 function may promote the distinctive aneuploidy characteristic of hypodiploid ALL. Moreover, the identification of hypodiploidy mandates offering testing for TP53 mutational status to patients and their relatives, with appropria...Continue Reading

References

May 14, 1999·Current Opinion in Immunology·M CortesK Georgopoulos
Sep 30, 1999·Human Mutation·D R Lohmann
Dec 7, 2000·Cancer Genetics and Cytogenetics·M L RamosE B Miranda
May 19, 2001·European Journal of Biochemistry·S H Liang, M F Clarke
Oct 5, 2001·Nature Reviews. Molecular Cell Biology·C J Sherr
Mar 7, 2002·Journal of Pediatric Hematology/oncology·J GumpS P Hunger
Aug 26, 2003·Cancer Genetics and Cytogenetics·P K DasA Smith
May 19, 2004·British Journal of Haematology·Christine J HarrisonUNKNOWN Childhood and Adult Leukaemia Working Parties
Aug 1, 2006·Cancer Genetics and Cytogenetics·Jennifer J D MorrissetteJ P de Chadarévian
Nov 15, 2006·Current Molecular Medicine·Amit Deshpande, Philip W Hinds
Mar 9, 2007·Nature·Charles G MullighanJames R Downing
May 3, 2007·Blood·James B NachmanGritta E Janka-Schaub
Apr 15, 2008·Nature·Charles G MullighanJames R Downing
Nov 29, 2008·Science·Charles G MullighanJames R Downing
Jan 9, 2009·The New England Journal of Medicine·Charles G MullighanUNKNOWN Children's Oncology Group
Nov 10, 2009·Blood·Anthony V MoormanStephen J Proctor
Feb 4, 2010·The Journal of Cell Biology·Sarah L Thompson, Duane A Compton
Nov 26, 2010·Proceedings of the National Academy of Sciences of the United States of America·Kajsa PaulssonBertil Johansson
Mar 11, 2011·Nature·Charles G MullighanJames R Downing
Jul 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jana HofRenate Kirschner-Schwabe
Oct 19, 2011·Journal of Cellular Biochemistry·Walter Hanel, Ute M Moll
May 23, 2012·Case Reports in Ophthalmology·Rivka KessnerMeira Neudorfer
Nov 17, 2012·Developmental Cell·Mathew J K Jones, Prasad V Jallepalli
Dec 21, 2012·Pediatric Blood & Cancer·Bradford C PowellSharon E Plon
Jan 22, 2013·Nature Genetics·Linda HolmfeldtCharles G Mullighan
Feb 28, 2013·Cancer Chemotherapy and Pharmacology·Carolyn D Britten
Sep 10, 2013·Nature Immunology·Hilde SchjervenStephen T Smale
Nov 20, 2013·Seminars in Hematology·Charles G Mullighan
Feb 11, 2014·Nature Immunology·Tanja A SchwickertMeinrad Busslinger
Mar 20, 2014·Nature Reviews. Clinical Oncology·Kate A McBrideGillian Mitchell

❮ Previous
Next ❯

Citations

Mar 9, 2017·Cold Spring Harbor Perspectives in Medicine·Tanya Guha, David Malkin
Jun 28, 2017·Experimental Hematology·Takaomi Sanda, Wei Zhong Leong
Dec 10, 2017·Hematology·Lisa J McReynolds, Sharon A Savage
Jul 26, 2019·Pediatric Blood & Cancer·Michaela KuhlenMichael C Frühwald
Apr 6, 2019·Current Drug Targets·Maryam Zanjirband, Soheila Rahgozar
Feb 3, 2019·Cold Spring Harbor Molecular Case Studies·Mahesh SwaminathanCourtney D DiNardo
Dec 14, 2018·Nature Reviews. Clinical Oncology·Ching-Hon PuiJun J Yang
Mar 14, 2019·Cancer Research·Ernesto Diaz-FloresMignon L Loh
Dec 12, 2020·Journal of Medical Ethics·Sapna Mehta, Dennis John Kuo
May 4, 2021·Genes, Chromosomes & Cancer·Thomas CreaseyAnthony V Moorman
Jul 5, 2021·BMC Medical Genomics·Martyna StefaniakMonika Lejman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.